

**Scope:** What is the long-term adverse health and quality of life effects of the most commonly used breast cancer adjuvant chemotherapy regimens?

**Key Questions**

1. In women with early stage breast cancer, how does the use of adjuvant hormonal therapy affect long-term adverse health outcomes and how does it differ by age, race/ethnicity, and hormone receptor status?
2. In women with early stage breast cancer treated with adjuvant hormonal therapy, how does the effect on long-term adverse health outcomes differ by adjuvant hormonal therapy treatment type?
  - a. What is the synergistic effect of the combination multiple adjuvant hormonal therapy types on long-term adverse health outcomes?
3. In with women with early stage breast cancer receiving adjuvant hormonal therapy, what is the impact of long-term health outcomes on patient quality of life?

**Other**

4. Among women with left-sided breast cancer, what is the impact of radiation on long-term adverse health outcomes?

**Research Approach**

Category	Include	Exclude
Population	Women of all ages with early stage (I-III A) breast cancer with any receptor status	Women with advanced stage (IIIB-IV)
Intervention	Adjuvant chemotherapy regimens (used alone or in combination) <ul style="list-style-type: none"><li>• Anthracyclines<ul style="list-style-type: none"><li>○ Doxorubicin</li><li>○ Epirubicin</li></ul></li><li>• Cyclophosphamide</li><li>• Taxanes</li><li>• Trastuzumab</li></ul>	
Comparisons	Women with early stage breast cancer who did not receive adjuvant chemotherapy	
Outcomes: Health	Chemotherapy-related long-term adverse health outcomes <ul style="list-style-type: none"><li>• Cardiac toxicity</li><li>• Ovarian failure</li><li>• Secondary malignancies</li><li>• Neurotoxicity</li><li>• Cognitive dysfunction</li></ul>	
Outcomes: Quality of Life	Quality of life	
Timing	Outcomes occurring or persisting beyond the first year of treatment	
Setting		
Study Design		
Language		
Data Sources		
Search Dates		